Competition stiff for DPP-4 inhibitors

Multinational pharmaceutical companies are stepping up their marketing in the dipeptidyl peptidase-4 (DPP-4) inhibitors in Korea, which is forecast to become more competitive than ever early next year, according to industry sources.

The enzyme DPP-4 normally breaks down a peptide, called GLP-1, that helps the body break down blood sugar. DPP-4 drugs are supposed to help patients control the...